NDA 019386 · Baxter Hlthcare
Brevibloc
Esmolol Hydrochloride · Injection
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Sep 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1986
Dec 31, 1986
Approved uses
3
Original approval plus efficacy supplements
Registered trials
99
17 Phase 3, 7 recruiting
FAERS reports
267
251 serious, 46 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 6, 2026.
1.1 Supraventricular Tachycardia or Noncompensatory Sinus Tachycardia BREVIBLOC (Esmolol Hydrochloride) injection is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. BREVIBLOC injection is also indicated in noncompensatory sinus tachycardia where, in the physician’s judgment, the rapid heart rate requires specific intervention. BREVIBLOC injection is intended for short-term use. 1.2 Intraoperative and Postoperative Tachycardia and/or Hypertension BREVIBLOC (Esmolol Hydrochloride) injection is indicated for the short-term treatment of tachycardia and hypertension that occur during induction and tracheal intubation, during surgery, on emergence from anesthesia and in the postoperative period, when in the physician’s judgment such specific intervention is considered indicated. Use of BREVIBLOC injection to prevent such events is not recommended. BREVIBLOC injection is a beta adrenergic blocker indicated for the short-term treatment of: •Control of ventricular rate in supraventricular tachycardia including atrial fibrillation and atrial flutter and control of heart rate in noncompensatory sinus tachycardia (1.1) •Control of perioperative tachycardia and hypertension (1.2)
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 18, 1992 Supplement 3 · Efficacy
- Dec 18, 1992 Supplement 8 · Efficacy
- Dec 31, 1986 Original approval · Type 1 - New Molecular Entity · priority review Review
6 products under this application
- BREVIBLOC · ESMOLOL HYDROCHLORIDE 10MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
- BREVIBLOC IN PLASTIC CONTAINER · ESMOLOL HYDROCHLORIDE 1GM/100ML · INJECTABLE, INJECTION · Prescription · TE AP
- BREVIBLOC · ESMOLOL HYDROCHLORIDE 250MG/ML · INJECTABLE, INJECTION · Discontinued
- BREVIBLOC · ESMOLOL HYDROCHLORIDE 20MG/ML · INJECTABLE, INJECTION · Discontinued
- BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER · ESMOLOL HYDROCHLORIDE 2GM/100ML · INJECTABLE, INJECTION · Prescription · TE AP
- BREVIBLOC · ESMOLOL HYDROCHLORIDE 10MG/ML · INJECTABLE, INJECTION · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Esmolol" as an intervention, any sponsor and status, largest first.
- Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED)Pivotal-lookingCompleted
The George InstituteAcademic, hospital or other
NCT01422616 · 4,587 participants · Start Mar 2012 · Primary completion Aug 2018
Drug: Low-dose rtPA; Standard-dose rtPA · For: Ischemic Stroke; High Blood Pressure
Sites: Sydney, Australia
- Effects of Low-dose Esmolol on Myocardial Injury After Non-cardiac Surgery in Elderly Frail PatientsPivotal-lookingRecruiting
Yongtao SunAcademic, hospital or other
NCT05635877 · 2,000 participants (planned) · Start Feb 7, 2023 · Primary completion Nov 30, 2026
Drug: Esmolol; Placebo Comparator: Placebo Comparator:normal saline(0.9%) · For: Frailty; Esmolol; Myocardial Injury
Sites: Jinan, China
- Efficacy of Esmolol in the Identification of Cardiovascular Disorders by Cirrhosis, Diabetes Mellitus and Cardiotoxic TreatmentsPivotal-lookingRecruiting
Consorcio Centro de Investigación Biomédica en Red (CIBER)Government (non-federal)
NCT05769868 · 1,000 participants (planned) · Start Apr 18, 2023 · Primary completion Mar 2027
Drug: Esmolol Injection [Brevibloc] · For: Cirrhosis; Diabetes Mellitus; Oncologic Disorders
Sites: Barcelona, Spain; Madrid, Spain; Salamanca, Spain · 6 sites in all
- Effect of Opioid-free Anaesthesia on Postoperative Delirium in Elderly Patients Undergoing Gastrointestinal SurgeryPivotal-lookingNot yet recruiting
Qianfoshan HospitalAcademic, hospital or other
NCT06958393 · 406 participants (planned) · Start May 20, 2025 · Primary completion Jan 5, 2026
Drug: Dexmedetomidine; Esketamine and 3 more · For: Delirium - Postoperative; Opioid-Free Anaesthesia
Sites: Jinan, China
- Intensive Blood Pressure Reduction in Acute Cerebral HaemorrhagePivotal-lookingCompleted
The George InstituteAcademic, hospital or other
NCT00226096 · 404 participants · Start Nov 2005 · Primary completion Sep 2007
Drug: Labetalol Hydrochloride; Metoprolol tartrate and 9 more · For: CVA (Cerebrovascular Accident); Cerebral Hemorrhage; Intracranial Hemorrhages
Sites: Concord, Australia; Gosford, Australia; Kogarah, Australia · 20 sites in all
- Study of Microvascular Dysfunction, CFR and Cardioprotective Effect of Early Administration of Esmolol in MIPivotal-lookingRecruiting
National Medical Research Center for Cardiology, Ministry of Health of Russian FederationGovernment (non-federal)
NCT06376630 · 300 participants (planned) · Start Jan 29, 2024 · Primary completion Jan 29, 2029
Drug: Esmolol Hcl 10Mg/Ml Inj · For: Myocardial Infarction; Coronary Stenosis; Coronary Microvascular Dysfunction
Sites: Moscow, Russia
- Manipulation of Arterial Pressure in Acute Ischemic StrokePivotal-lookingStatus unknown
Hospital de Clinicas de Porto AlegreAcademic, hospital or other
NCT00848770 · 240 participants (planned) · Start Jan 2008 · Primary completion Dec 2010
Drug: Esmolol, Sodium Nitroprussiate (NPS) or Norepinephrine (NOR); Esmolol, NPS or NOR and 1 more · For: Stroke, Acute
Sites: Porto Alegre, Brazil
- Esmolol in Cardiac SurgeryPivotal-lookingCompleted
Università Vita-Salute San RaffaeleAcademic, hospital or other
NCT00959569 · 200 participants · Start Aug 2009 · Primary completion May 2018
Drug: Esmolol; Placebo · For: Cardiac Surgery
Sites: Milan, Italy
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective36
- cardiac arrest21
- hypotension20
- bradycardia17
- product use issue15
- product use in unapproved indication12
- renal failure10
- ventricular fibrillation10
- hypertension9
- acute kidney injury8
- atrial fibrillation8
- death8
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 6 |
| 2005 | 6 |
| 2006 | 5 |
| 2007 | 7 |
| 2008 | 4 |
| 2009 | 10 |
| 2010 | 6 |
| 2011 | 14 |
| 2012 | 6 |
| 2013 | 9 |
| 2014 | 7 |
| 2015 | 21 |
| 2016 | 17 |
| 2017 | 10 |
| 2018 | 15 |
| 2019 | 14 |
| 2020 | 13 |
| 2021 | 16 |
| 2022 | 14 |
| 2023 | 21 |
| 2024 | 11 |
| 2025 | 26 |
| 2026 | 9 |
Recalls
2 FDA enforcement reports for this application.
Apr 12, 2016 · Class II · Terminated
Discoloration: presence of atypical yellow discoloration of the solution .
Jun 16, 2014 · Class II · Terminated
Presence of Particulate Matter: Complaints received of discolored solution identified as subvisible particles of iron oxide that are agglomerating.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Brevibloc* (Esmolol HCL*) · HCPCS J1805
2024 spending
$73K
Beneficiaries
6,530
7,479 claims
Per beneficiary
$11
2024 ASP limit $0.23 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $37 |
| 2024 | $72,801 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Beyond the Surviving Sepsis Campaign Guidelines: a systematic review of interventions affecting mortality in sepsis.
Sartini C, Landoni G, Belletti A, et al. · Panminerva Med 2024 · Systematic Review
- Esmolol.
Bleske BE · Conn Med 1987 · Clinical Trial, Research Support, Non-U.S. Gov't
- Comparison of Esmolol Versus Landiolol on Mortality in Adult Patients With Sepsis: A Systematic Review and Network Meta-Analysis.
Tang Z, Sun Q, Xu J, et al. · Crit Care Med 2026 · Systematic Review, Meta-Analysis
- Esmolol as an Adjunct in Multimodal Anesthesia: A Systematic Review and Meta-Analysis of Its Opioid-Sparing and Analgesic Effects.
Neto EDDS, de Lara FST, Abreu SN, et al. · Anesth Analg 2026 · Systematic Review, Meta-Analysis
- Combined femoral artery block and femoral nerve block reduces thigh tourniquet-induced hypertension.
Xu F, Wang X, Li Y, et al. · J Clin Anesth 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial.
Morelli A, Ertmer C, Westphal M, et al. · JAMA 2013 · Clinical Trial, Phase II, Randomized Controlled Trial
Sponsor: Baxter Hlthcare · Also marketed as Brevibloc In Plastic Container, Brevibloc Double Strength In Plastic Container
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.